CDXC - ChromaDex Corp Stock Price, Fair Value and News

3.29USD-0.19 (-5.46%)Market Closed

Market Summary

USD3.29-0.19

Market Closed

-5.46%

CDXC Stock Price

View Fullscreen

CDXC RSI Chart

CDXC Valuation

Market Cap

248.5M

Price/Earnings (Trailing)

-70.44

Price/Sales (Trailing)

2.99

EV/EBITDA

-17.6

Price/Free Cashflow

53.89

CDXC Price/Sales (Trailing)

CDXC Profitability

Operating Margin

60.98%

EBT Margin

-19.88%

Return on Equity

-12.19%

Return on Assets

-6.52%

Free Cashflow Yield

1.86%

CDXC Fundamentals

CDXC Revenue

Revenue (TTM)

83.2M

Rev. Growth (Yr)

-1.79%

Rev. Growth (Qtr)

4.52%

CDXC Earnings

Earnings (TTM)

-3.5M

Earnings Growth (Yr)

74.13%

Earnings Growth (Qtr)

-531.58%

Breaking Down CDXC Revenue

Last 7 days

-3.8%

Last 30 days

-17.1%

Last 90 days

103.1%

Trailing 12 Months

110.9%

How does CDXC drawdown profile look like?

CDXC Financial Health

Current Ratio

2.52

CDXC Investor Care

Shares Dilution (1Y)

0.76%

Diluted EPS (TTM)

-0.05

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	83.2M	0	0	0
2023	77.3M	80.9M	83.4M	83.6M
2022	70.0M	69.1M	68.8M	72.0M
2021	59.6M	62.0M	65.1M	67.4M
2020	50.6M	54.8M	56.9M	59.3M
2019	35.0M	38.3M	42.3M	46.3M
2018	24.4M	28.0M	30.0M	31.6M
2017	19.2M	16.0M	18.1M	21.2M
2016	22.6M	23.9M	21.6M	21.7M
2015	17.5M	19.7M	21.9M	22.0M
2014	10.9M	12.0M	13.5M	15.3M
2013	12.2M	12.2M	11.3M	10.2M
2012	7.4M	8.1M	9.9M	11.6M
2011	7.7M	7.8M	8.0M	8.1M
2010	0	0	0	7.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ChromaDex Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 01, 2023	gerber brianna	bought	7,050	1.41	5,000	chief financial officer
Sep 06, 2023	champion river ventures ltd	bought	-	-	3,467,780	-
Aug 12, 2023	gerber brianna	acquired	-	-	22,436	chief financial officer
Jun 12, 2023	jaksch frank l jr	bought	11,830	1.69	7,000	-
May 31, 2023	fried robert n	bought	9,940	1.42	7,000	chief executive officer
May 25, 2023	rubin steven d	bought	10,220	1.46	7,000	-
Sep 30, 2022	chau hoi shuen solina holly	bought	1,200,000	1.25	960,000	-
Sep 30, 2022	fried robert n	bought	100,000	1.25	80,000	cheif executive officer
Jun 16, 2022	chau hoi shuen solina holly	bought	99,877	1.6636	60,037	-
Mar 16, 2022	fried robert n	bought	54,000	2.16	25,000	ceo

Which funds bought or sold CDXC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	421	731,693	794,257	-%
May 15, 2024	Royal Bank of Canada	added	55.43	474,000	644,000	-%
May 15, 2024	Kestra Advisory Services, LLC	unchanged	-	43,050	73,080	-%
May 15, 2024	BARCLAYS PLC	sold off	-100	-5,000	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	1,434	69,128	71,030	-%
May 15, 2024	Point72 Asia (Singapore) Pte. Ltd.	new	-	211,205	211,205	0.06%
May 15, 2024	Squarepoint Ops LLC	reduced	-41.1	38,368	126,884	-%
May 15, 2024	Man Group plc	new	-	61,057	61,057	-%
May 15, 2024	Cubist Systematic Strategies, LLC	new	-	31,323	31,323	-%
May 15, 2024	ICONIQ Capital, LLC	unchanged	-	2,657,530	4,511,310	0.08%

Are Funds Buying or Selling CDXC?

Are funds buying CDXC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CDXC

No. of Funds

Unveiling ChromaDex Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Sep 07, 2023	champion river ventures ltd	10.58%	7,940,937	SC 13D/A
Oct 19, 2022	societe des produits nestle s.a.	5.11%	3,816,794	SC 13G
Oct 03, 2022	champion river ventures ltd	11.21%	7,940,937	SC 13D/A
Oct 03, 2022	pioneer step holdings ltd	9.77%	6,917,783	SC 13D/A
May 20, 2022	pioneer step holdings ltd	8.72%	5,957,783	SC 13D/A
May 20, 2022	shing li ka	9.51%	6,500,937	SC 13D/A
Feb 11, 2022	li ka shing (global) foundation	5.08%	3,467,778	SC 13G/A
Feb 11, 2022	yong rong (hk) asset management ltd	8.52%	5,819,802	SC 13G/A
Sep 21, 2021	chau hoi shuen solina holly	8.74%	5,957,783	SC 13D/A
Sep 20, 2021	chau hoi shuen solina holly	8.74%	5,957,783	SC 13D/A

Recent SEC filings of ChromaDex Corp

View All Filings

Date Filed	Form Type	Document
May 08, 2024	8-K	Current Report
May 08, 2024	10-Q	Quarterly Report
Apr 25, 2024	DEFA14A	DEFA14A
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	ARS	ARS
Mar 06, 2024	8-K	Current Report
Mar 06, 2024	10-K	Annual Report
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading

Peers (Alternatives to ChromaDex Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

ChromaDex Corp News

Latest updates

ChromaDex Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	4.5%	22,153	21,196	19,495	20,323	22,556	20,996	17,063	16,732	17,259	17,759	17,308	17,699	14,683	15,445	14,180	15,287	14,345	13,089	12,053	11,101	10,048
Cost Of Revenue	5.3%	8,697	8,259	7,526	7,967	9,038	8,980	6,856	6,690	6,727	6,891	6,730	6,889	5,449	6,024	5,726	6,199	6,034	5,624	5,304	4,847	4,747
Gross Profit	4.0%	13,456	12,937	11,969	12,356	13,518	12,016	10,207	10,042	10,532	10,868	10,578	10,810	9,234	9,421	8,454	9,088	8,311	7,465	6,749	6,254	5,301
Operating Expenses	8.3%	14,187	13,105	13,116	14,672	15,486	13,460	13,272	16,429	18,264	16,184	19,419	16,364	16,596	15,502	12,650	12,775	14,201	16,325	13,637	13,434	13,673
S&GA Expenses	3.4%	6,740	6,520	6,035	6,009	7,874	6,187	5,868	8,021	8,237	8,641	7,221	6,232	6,258	6,319	5,223	4,959	4,447	5,108	4,626	4,308	4,174
R&D Expenses	80.8%	2,095	1,159	1,241	1,365	1,193	1,279	1,224	1,245	1,078	1,045	996	1,004	787	815	841	895	919	1,139	1,044	1,069	1,168
EBITDA Margin	0.7%	-0.18*	-0.18*	-0.18*	-0.19*	-0.20*	-0.22*	-0.23*	-0.23*	-0.22*	-0.23*	-0.24*	-0.25*	-	-	-	-	-	-	-	-	-
Interest Expenses	-15.2%	239	282	188	125	66.00	26.00	-5.00	-10.00	-8.00	-101	15.00	12.00	19.00	16.00	19.00	24.00	12.00	-42.00	314	575	35.00
EBT Margin	-0.5%	-0.20*	-0.20*	-0.20*	-0.20*	-0.21*	-0.23*	-0.24*	-0.24*	-0.24*	-0.25*	-0.25*	-0.27*	-	-	-	-	-	-	-	-	-
Net Income	-531.6%	-492	114	-959	-2,191	-1,902	-1,418	-985	-6,397	-7,740	-5,325	-8,856	-5,566	-7,381	-6,097	-4,215	-3,711	-5,902	-8,853	-7,202	-7,755	-8,337
Net Income Margin	28.2%	-0.04*	-0.06*	-0.08*	-0.08*	-0.14*	-0.23*	-0.30*	-0.41*	-0.39*	-0.40*	-0.43*	-0.38*	-	-	-	-	-	-	-	-	-
Free Cashflow	-52.2%	295	617	388	3,232	2,760	-368	-3,780	-3,872	-7,238	-4,984	-5,959	-7,935	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-1.6%	54.00	55.00	53.00	53.00	54.00	54.00	46.00	47.00	53.00	58.00	60.00	66.00	69.00	38.00	37.00	42.00	36.00	40.00	43.00	45.00	42.00
Current Assets	-1.1%	49.00	50.00	47.00	46.00	47.00	47.00	38.00	39.00	45.00	49.00	53.00	58.00	63.00	32.00	31.00	36.00	29.00	34.00	36.00	38.00	35.00
Cash Equivalents	0.9%	28.00	27.00	27.00	26.00	23.00	20.00	13.00	17.00	21.00	28.00	33.00	39.00	45.00	17.00	15.00	19.00	14.00	19.00	19.00	20.00	19.00
Inventory	-14.0%	12.00	15.00	13.00	12.00	12.00	15.00	16.00	16.00	15.00	14.00	13.00	12.00	13.00	12.00	11.00	12.00	11.00	12.00	10.00	11.00	9.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	3.00	3.00	3.00	3.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00
Liabilities	-5.2%	25.00	27.00	26.00	26.00	26.00	25.00	25.00	26.00	27.00	26.00	25.00	24.00	25.00	22.00	18.00	20.00	19.00	20.00	16.00	29.00	21.00
Current Liabilities	-5.7%	19.00	21.00	19.00	19.00	18.00	18.00	17.00	18.00	19.00	18.00	18.00	16.00	20.00	16.00	13.00	16.00	14.00	15.00	11.00	24.00	16.00
Shareholder's Equity	1.7%	29.00	28.00	27.00	27.00	28.00	29.00	21.00	21.00	26.00	32.00	35.00	42.00	44.00	16.00	19.00	22.00	17.00	20.00	27.00	15.00	21.00
Retained Earnings	-0.3%	-190	-190	-190	-189	-187	-185	-184	-183	-176	-168	-163	-154	-149	-141	-135	-131	-127	-121	-113	-105	-98.09
Additional Paid-In Capital	0.4%	220	219	218	217	215	214	205	204	203	201	199	197	193	158	155	153	144	142	140	121	119
Shares Outstanding	0.2%	75.00	75.00	75.00	75.00	75.00	75.00	68.00	68.00	68.00	68.00	67.00	66.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	81.00	-	-	-	79.00	-	-	-	474	-	-	-	190	-	-	-	190	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-52.2%	295	617	428	3,272	2,800	-328	-3,740	-3,832	-7,198	-4,944	-5,919	-7,895	-5,405	22.00	-3,845	-1,556	-5,221	-610	-7,760	-9,021	-3,048
Share Based Compensation	-5.1%	984	1,037	1,117	1,324	1,273	1,326	1,229	1,296	1,888	1,473	1,822	1,616	1,284	1,778	1,574	1,711	1,873	1,698	1,686	1,759	2,029
Cashflow From Investing	-95.2%	-41.00	-21.00	-26.00	-5.00	-91.00	-172	-52.00	-85.00	-25.00	-2.00	-96.00	-265	-46.00	16.00	-59.00	-102	-20.00	272	-156	-69.00	-296
Cashflow From Financing	81.6%	-14.00	-76.00	-3.00	-10.00	-1.00	7,679	-18.00	-4.00	-3.00	63.00	339	2,247	33,445	1,181	492	6,940	37.00	271	7,035	9,523	55.00
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CDXC Income Statement

2024-03-31

Unaudited Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Sales, net	$ 22,153	$ 22,556
Cost of sales	8,697	9,038
Gross profit	13,456	13,518
Operating expenses:
Sales and marketing	6,740	7,874
Research and development	2,095	1,193
General and administrative	5,352	6,419
Total operating expenses	14,187	15,486
Operating loss	(731)	(1,968)
Nonoperating income:
Interest income, net	239	66
Net loss	$ (492)	$ (1,902)
Basic loss per common share attributable to ChromaDex Corporation (in dollars per share)	$ (0.01)	$ (0.03)
Diluted loss per common share attributable to ChromaDex Corporation (in dollars per share)	$ (0.01)	$ (0.03)
Basic weighted average common shares outstanding (in shares)	75,230	74,796
Diluted weighted average common shares outstanding (in shares)	75,230	74,796

CDXC Balance Sheet

2024-03-31

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents, including restricted cash of $152 for both periods presented	$ 27,565	$ 27,325
Trade receivables, net of allowances of $87 and $68, respectively; Including receivables from Related Party of $2.7 million and $2.8 million, respectively	6,604	5,234
Inventories	12,495	14,525
Prepaid expenses and other assets	2,312	2,450
Total current assets	48,976	49,534
Leasehold improvements and equipment, net	2,000	2,137
Intangible assets, net	472	510
Right-of-use assets, net	2,226	2,400
Other long-term assets	405	383
Total assets	54,079	54,964
Current liabilities
Accounts payable	7,899	10,232
Accrued expenses	10,465	9,493
Current maturities of operating lease obligations	850	691
Current maturities of finance lease obligations	11	11
Customer deposits	227	195
Total current liabilities	19,452	20,622
Deferred revenue	3,311	3,311
Operating lease obligations, less current maturities	2,356	2,563
Finance lease obligations, less current maturities	9	12
Total liabilities	25,128	26,508
Commitments and Contingencies (Note 10)
Stockholders' Equity
Common stock, $0.001 par value; authorized 150,000 shares; 75,153 shares and 74,981 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	75	75
Additional paid-in capital	219,829	218,845
Accumulated deficit	(190,952)	(190,460)
Cumulative translation adjustments	(1)	(4)
Total stockholders' equity	28,951	28,456
Total liabilities and stockholders' equity	$ 54,079	$ 54,964

About ChromaDex Corp

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

CEO	Mr. Robert N. Fried
WEBSITE	chromadex.com
INDUSTRY	Biotechnology
EMPLOYEES	113

ChromaDex Corp Frequently Asked Questions

What is the ticker symbol for ChromaDex Corp? What does CDXC stand for in stocks?

CDXC is the stock ticker symbol of ChromaDex Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ChromaDex Corp (CDXC)?

As of Fri May 17 2024, market cap of ChromaDex Corp is 248.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CDXC stock?

You can check CDXC's fair value in chart for subscribers.

What is the fair value of CDXC stock?

You can check CDXC's fair value in chart for subscribers. The fair value of ChromaDex Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ChromaDex Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CDXC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ChromaDex Corp a good stock to buy?

The fair value guage provides a quick view whether CDXC is over valued or under valued. Whether ChromaDex Corp is cheap or expensive depends on the assumptions which impact ChromaDex Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CDXC.

What is ChromaDex Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CDXC's PE ratio (Price to Earnings) is -70.44 and Price to Sales (PS) ratio is 2.99. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CDXC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ChromaDex Corp's stock?

In the past 10 years, ChromaDex Corp has provided -0.034 (multiply by 100 for percentage) rate of return.